Yes whytee but...
GvHD in children has no current treatment, and mortality approaching 90%.
That fits the purpose of the accelerated approval program - which is used when a product would normally require another trial, but there is unmet need.
Accelerated approval requires post sale confirmatory phase 4 trial - which is what the company said it is asking for, and they would conduct it in adults.
So unless the FDA want to go against their own program advice, and the panel of experts they asked for advice from given they have almost no experience in Stems....Mesoblast will get what they are asking for.
the above is my opinion, which will be proven wrong or right " in short order "![]()
- Forums
- ASX - By Stock
- MSB
- Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-190
-
- There are more pages in this discussion • 219 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 86854 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16000 | 0.965 |
1 | 23000 | 0.960 |
4 | 56273 | 0.955 |
5 | 46225 | 0.950 |
2 | 65500 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 50000 | 2 |
0.975 | 20000 | 1 |
0.980 | 894 | 1 |
0.985 | 48122 | 2 |
0.990 | 54328 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online